Alkermes (NASDAQ:ALKS) updated its FY 2020
Pre-Market earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.25-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.44. The company issued revenue guidance of $1.03-1.08 billion, compared to the consensus revenue estimate of $1.06 billion.Alkermes also updated its FY20 guidance to $0.25 to $0.43 EPS.
A number of analysts have recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Alkermes from $26.00 to $25.00 and set a neutral rating for the company in a report on Friday. JPMorgan Chase & Co. downgraded shares of Alkermes from an overweight rating to a neutral rating and dropped their price objective for the stock from $25.00 to $21.00 in a report on Thursday. Cowen reaffirmed a buy rating and set a $28.00 price objective on shares of Alkermes in a report on Friday. Wolfe Research raised shares of Alkermes from an underperform rating to a peer perform rating and set a $21.00 price objective for the company in a report on Friday, January 31st. Finally, Svb Leerink reaffirmed a market perform rating on shares of Alkermes in a report on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the stock. Alkermes presently has an average rating of Hold and a consensus price target of $22.92.
NASDAQ:ALKS traded up $0.12 during trading hours on Friday, reaching $17.77. The company’s stock had a trading volume of 3,334,635 shares, compared to its average volume of 1,555,217. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -13.78 and a beta of 1.97. The firm has a 50-day simple moving average of $18.89 and a 200-day simple moving average of $20.09. Alkermes has a 1 year low of $16.65 and a 1 year high of $37.75. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.42 and a current ratio of 2.69.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.18. The company had revenue of $412.70 million for the quarter, compared to analysts’ expectations of $404.45 million. Alkermes had a negative net margin of 18.71% and a negative return on equity of 6.08%. The firm’s revenue was up 30.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 EPS. Equities analysts anticipate that Alkermes will post -0.16 earnings per share for the current fiscal year.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Further Reading: What is a capital gain?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.